Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.59%-3.35%+52.37%+91.62% 6.95TCr
-1.34%-0.75%+48.21%+92.23% 6.5TCr
-4.17%-0.12%+34.91%+9.94% 2.65TCr
-2.35%-5.75%-12.90%+436.87% 2.59TCr
-8.37%-12.43%+2.08%-18.39% 2.56TCr
-0.96%+10.36%+283.06%+429.04% 2.02TCr
-0.51%+0.23%+35.77%-19.61% 2TCr
-3.91%-5.54%+1.65%+545.75% 1.57TCr
-1.47%+0.68%+45.51%+142.00% 1.35TCr
Average -2.47%-1.93%+54.52%+189.94% 3.13TCr
Weighted average by Cap. -2.47%-1.50%+51.42%+149.77%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-